BOLD imaging of tumors

New Techniques in Oncologic Imaging

Volumn , Issue , 2005, Pages 257-272

  Robinson, Simon P ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77949952106     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (65)

1. Molls M, Vaupel P. Blood perfusion and microenvironment of human tumors. Implications for Clinical Radiooncology. Berlin: Springer-Verlag, 1998.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-257.
3. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84:1875-1887.
4. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 1995; 177:275-283.
5. Cooper RA, Wilks DP, Logue J, et al. High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin Cancer Res 1998; 4:2795-2800.
6. Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999; 80(suppl 1):57-64.
7. Gillies RJ, Bhujwalla ZM, Evelhoch JL, et al. Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia 2000; 2:139-151.
8. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. MRI of the tumor microenvironment. J Magn Reson Imag 2002; 16:430-450.
9. Ogawa S, Lee TM, Nayak AS, Glynn P. Oxygenation-sensitive contrast in magnetic resonance image of rodent brain at high magnetic fields. Magn Reson Med 1990; 14:68-78.
10. Ogawa S, Menon RS, Kim SG, Ugurbil K. On the characteristics of functional magnetic resonance imaging of the brain. Annu Rev Biophys Biomol Struct 1998; 27:447-474.
11. 2_ and resonance frequency weighted magnetic resonance images of rodent tumours. NMR Biomed 1994; 7:3-11.
12. Robinson SP, Howe FA, Griffiths JR. Noninvasive monitoring of carbogen-induced changes in tumor blood flow and oxygenation by functional magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1995; 33:855-859.
13. 2_- weighted images during hyperoxia differentiate tumors from normal tissues. Magn Reson Med 1995; 33:318-325.
14. Robinson SP, Rodrigues LM, Ojugo ASE, McSheehy PMJ, Howe FA, Griffiths JR. The response to carbogen breathing in experimental tumour models monitored by gradientrecalled magnetic resonance imaging. Br J Cancer 1997; 75:1000-1006.
15. Robinson SP, Collingridge DR, Rodrigues LM, Howe FA, Chaplin DJ, Griffiths JR. Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. NMR Biomed 1999; 12:98-106.
16. Howe FA, Robinson SP, Griffiths JR. Modification of tumor perfusion and oxygenation monitored by gradient recalled echo MRI and 31P MRS. NMR Biomed 1996; 9:208-216.
17. Howe FA, Robinson SP, Rodrigues LM, Griffiths JR. Flow oxygenation dependent (FLOOD) contrast MR imaging to monitor the response of rat tumours to carbogen breathing. Magn Reson Imag 1999; 17:1307-1318.
18. Oikawa H, Al-Hallaq HA, Lewis MZ, River JN, Kovar DA, Karczmar GS. Spectroscopic imaging of the water resonance with short repetition time to study tumor response to hyperoxia. Magn Reson Med 1997; 38:27-32.
19. 2_ response after carbogen breathing (abstr). Proceedings of the International Society for Magnetic Resonance in Medicine 1997; 2082.
20. Abramovitch R, Frenkiel D, Neeman M. Analysis of subcutaneous angiogenesis by gradient echo magnetic resonance imaging. Magn Reson Med 1998; 39:813-824.
21. Peller M, Weissfloch L, Stehling MK, et al. Oxygen-induced MR signal changes in murine tumors. Magn Reson Imag 16; 7:799-809.
22. Al-Hallaq HA, River JN, Zamora M, Oikawa H, Karczmar GS. Correlation of magnetic resonance and oxygen microelectrode measurements of carbogen-induced changes in tumor oxygenation. Int J Radiat Oncol Biol Phys 1998; 41:151-159.
23. Al-Hallaq HA, Zamora M, Fish BL, Farrell A, Moulder JE, Karczmar GS. MRI measurements correctly predict the relative effects of tumor oxygenating agents on hypoxic fraction in rodent BA1112 tumors. Int J Rad Oncol Biol Phys 2000; 47:481-488.
24. Al-Hallaq HA, Fan X, Zamora M, River JN, Moulder JE, Karczmar GS. Spectrally inhomogeneous BOLD contrast changes detected in rodent tumors with high spectral and spatial resolution. NMR Biomed 2002; 15:28-36.
25. Landuyt W, Hermans R, Bosmans H, et al. BOLD contrast fMRI of whole rodent tumour during air or carbogen breathing using echo-planar imaging at 1.5T. Eur Radiol 2001; 11:2332-2340.
26. Griffiths JR, Taylor NJ, Howe FA, et al. The response of human tumors to carbogen breathing, monitored by gradient-recalled echo magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1997; 39:697-701.
27. Taylor NJ, Baddeley H, Goodchild KA, et al. BOLD MRI of human tumour oxygenation during carbogen breathing. J Magn Reson Imaging 2001; 14:156-163.
28. Robinson SP, Howe FA, Stubbs M, Griffiths JR. Effects of nicotinamide and carbogen on tumour oxygenation, blood flow, energetics and blood glucose levels. Br J Cancer 2000; 82:2007-2014.
29. Muruganandham M, Kasiviswanathan A, Jagannathan NR, Raghunathan P, Jain PC, Jain V. Diltiazem enhances tumor blood flow: MRI study in a murine tumor. Int J Radiat Oncol Biol Phys 1999; 43:413-421.
30. Jordan BF, Misson P, Demeure R, Baudelet C, Beghein N, Gallez B. Changes in tumor oxygenation/perfusion induced by the NO donor isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 2000; 48:565-570.
31. Robinson SP, Howe FA, Griffiths JR. Tumour response to the nitric oxide donor SIN-1 monitored by GRE MRI and 31P MRS. Proceedings of the International Society for Magnetic Resonance in Medicine 1997; 1092.
32. Lankester KJ, Hill SA, Tozer GM, Maxwell RJ. BOLD-MRI responses to vasoactive agents: influence of vessel maturity. Proceedings of the International Society for Magnetic Resonance in Medicine Workshop on In Vivo Functional and Molecular Assessment of Cancer, Santa Cruz, USA, 2002:18.
33. Howe FA, Robinson SP, McIntyre DJO, Stubbs M, Griffiths JR. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 2001; 7:497-506.
34. 2_ and arterial blood gases. Magn Reson Imag 2001; 19:161-166.
35. 2) inside tumors? Magn Reson Med 2002; 48:980-986.
36. Dunn JF, O’Hara JA, Zain-Wadghiri Y, et al. Changes in oxygenation of intracranial tumors with carbogen: a BOLD MRI and EPR oximetry study. J Magn Reson Imag 2002; 16:511-521.
37. 2_ maps obtained from BOLD images. Proceedings of the International Society for Magnetic Resonance in Medicine 2002; 2065.
38. Rijpkema M, Kaanders JHAM, Joosten FBM, van der Kogel AJ, Heerschap A. Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head and neck tumors as measured by MRI. Int J Radiat Oncol Biol Phys 2002; 53:1185-1191.
39. Robinson SP, Rijken PFJW, Howe FA, et al. Tumour vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. J Magn Reson Imag 2003; 17:445-454.
40. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 1998; 40:793-799.
41. Tropres I, Grimault S, Vaeth A, et al. Vessel size imaging. Magn Reson Med 2001; 45:397-408.
42. Hunjan S, Zhao D, Constantinescu A, Hahn EW, Antich PP, Mason RP. Tumor oximetry:demonstration of an enhanced dynamic mapping procedure using fluorine-19 echo planar magnetic resonance imaging in the Dunning prostate R3327-AT1 rat tumor. Int J Radiat Oncol Biol Phys 2001; 49:1097-1108.
43. 2 using a fibre-optic oxygen sensor in rodent tumours and their response to carbogen breathing. Proceedings of the International Society for Magnetic Resonance in Medicine 1998; 1665.
44. 2_ is a prognostic indicator of acute radiotherapeutic response in rodent tumors. J Magn Reson Imaging. 2004; 19:482-488.
45. Taylor NJ, Carnell DM, Smith RE, et al. Evaluation of prostate gland hypoxia with quantified BOLD MRI: initial results from a correlated histological study. Proceedings of the International Society for Magnetic Resonance in Medicine 2003; 531.
46. Kostourou V, Troy H, Murray JF, Cullis ER, Whitley GS, Griffiths JR, Robinson SP. Overexpression of dimethylarginine dimethylaminohydrolase enhances tumour hypoxia:an insight into the relationship of hypoxia and angiogenesis in vivo. Neoplasia 2004; 6:401-411.
47. Abramovitch R, Meir G, Neeman M. Neovascularization induced growth of implanted C6 glioma multicellular spheroids: magnetic resonance microimaging. Cancer Res 1995; 55:1956-1962.
48. Gilead A, Neeman M. Dynamic remodeling of the vascular bed precedes tumor growth:MLS ovarian carcinoma spheroids implanted in nude mice. Neoplasia 1999; 1:226-230.
49. Abramovitch R, Marikovsky M, Meir G, Neeman M. Stimulation of tumour angiogenesis by proximal wounds: spatial and temporal analysis by MRI. Br J Cancer 1998; 77:440-447.
50. Schiffenbauer YS, Abramovitch R, Meir G, et al. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acas Sci 1997; 94:13,203-13,208.
51. Abramovitch R, Dafni H, Neeman M, Nagler A, Pines M. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia 1999; 1:321-329.
52. Gross DJ, Reibstein I, Weiss L, et al. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clin Cancer Res 2003; 9:3788-3793.
53. Shaharabany M, Abramovitch R, Kushnir T, et al. In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs breast tumors. Cancer Res 2001; 61:4873-4878.
54. Griffiths JR, McSheehy PM, Robinson SP, et al. Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible-factor-1b (HIF-1b): evidence of an anabolic role for the HIF-1 pathway. Cancer Res 2002; 62:688-695.
55. Kostourou V, Robinson SP, Cartwright JE, Whitley GS. Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer 2002; 87:673-680.
56. Abramovitch R, Dafni H, Smouha E, Benjamin LE, Neeman M. In vivo prediction of vascular susceptibility to vascular endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res 1999; 59:5012-5016.
57. Neeman M, Dafni H, Bukhari O, Braun RD, Dewhirst MW. In vivo BOLD contrast MRI mapping of subcutaneous vascular function and maturation: validation by intravital microscopy. Magn Reson Med 2001; 45:887-898.
58. Carmeliet P, Dor Y, Herbert J-M, et al. Role of HIF-1a in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394:485-490.
59. Gross DJ, Reibstein I, Weiss L, et al. The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice. Clin Cancer Res 1999; 5:3669-3675.
60. Goldshmidt O, Zcharia E, Abramovitch R, et al. Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci 2002; 99:10,031-10,036.
61. Kostourou V, Robinson SP, Whitley GS, Griffiths JR. Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumour angiogenesis assessed by susceptibility magnetic resonance imaging. Cancer Res 2003; 63:4960-4966.
62. Robinson SP, McIntyre DJO, Checkley D, et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003; 88:1592-1597.
63. Blakey DC, Westwood FR, Walker M, et al. Anti-tumour activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002; 8:1974-1983.
64. Du W, Du YP, Bick U, et al. BreastMRimaging with high spectral and spatial resolutions:preliminary experience. Radiology 2002; 224:577-585.
65. Robinson SP, Kalber TL, Howe FA, et al. Acute tumor response to ZD6126 assessed by intrinsic-susceptibility magnetic resonance imaging. Neoplasia 2005; 7:466-474.